Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Sowa-Staszczak A, Pach D, Stefańska A, Tomaszuk M, Lenda-Tracz W, Mikołajczak R, Pawlak D, Chrzan R, Gilis-Januszewska A, Przybylik-Mazurek E, Hubalewska-Dydejczyk A.

Nucl Med Rev Cent East Eur. 2011;14(2):73-8.

2.

Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.

Pach D, Sowa-Staszczak A, Kunikowska J, Królicki L, Trofimiuk M, Stefańska A, Tomaszuk M, Głowa B, Mikołajczak R, Pawlak D, Jabrocka-Hybel A, Hubalewska-Dydejczyk AB.

Radiother Oncol. 2012 Jan;102(1):45-50. doi: 10.1016/j.radonc.2011.08.006. Epub 2011 Aug 30.

PMID:
21885142
3.

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.

Sowa-Staszczak A, Pach D, Kunikowska J, Krolicki L, Stefanska A, Tomaszuk M, Buziak-Bereza M, Mikolajczak R, Matyja M, Gilis-Januszewska A, Jabrocka-Hybel A, Trofimiuk M, Hubalewska-Dydejczyk A.

Endokrynol Pol. 2011;62(5):392-400.

4.

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, Cacciari G, Delle Fave G, Falconi M, Tomassetti P.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1197-205. doi: 10.1007/s00259-013-2402-2. Epub 2013 Apr 26.

PMID:
23619938
5.

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.

Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. Epub 2005 Jul 15.

PMID:
16021448
6.

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.

Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ.

Acta Oncol. 2007;46(6):723-34. Review.

PMID:
17653893
7.

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R.

Ann Oncol. 1999;10 Suppl 2:S23-9.

PMID:
10399029
8.

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.

Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Print 2011 Oct. Review.

9.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

10.

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.

Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, Bodei L, Garaboldi L, Bartolomei M, Paganelli G.

Neuroendocrinology. 2013;97(4):347-54. doi: 10.1159/000348394. Epub 2013 May 22.

PMID:
23392072
11.

Tumor imaging and therapy using radiolabeled somatostatin analogues.

de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.

Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.

PMID:
19445476
12.

68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M.

J Nucl Med. 2010 Sep;51(9):1349-56. doi: 10.2967/jnumed.110.075002. Epub 2010 Aug 18.

13.

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP.

Semin Nucl Med. 2006 Apr;36(2):147-56.

PMID:
16517236
14.

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):867-81. doi: 10.1016/j.bpg.2013.01.004.

PMID:
23582925
15.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G.

Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3.

PMID:
21892623
16.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
17.

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

Kaltsas GA, Papadogias D, Makras P, Grossman AB.

Endocr Relat Cancer. 2005 Dec;12(4):683-99. Review.

18.

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).

Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska-Dydejczyk A.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1669-74. doi: 10.1007/s00259-011-1835-8. Epub 2011 May 11.

19.

Peptide-receptor radionuclide therapy for endocrine tumors.

van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ.

Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Review.

PMID:
19488074
20.

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.

Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, Weissman H, Palmer DH, Vora J, Pritchard DM, Cuthbertson DJ.

Br J Cancer. 2013 Apr 16;108(7):1440-8. doi: 10.1038/bjc.2013.103. Epub 2013 Mar 14.

Items per page

Supplemental Content

Write to the Help Desk